

Haematologica
HAEMATOL/2020/262691
Version 3

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications

David M. Ross, Jeffrey J. Babon, Denis Tvorogov, and Daniel Thomas

Disclosures: No support received for the work under consideration. DMR has received research funding and honoraria from Novartis and BMS/Celgene. JJB, DTv and DTh declare no conflict of interest.

Contributions: DMR and DTh reviewed the literature and wrote the paper. JJB and DTv critically reviewed the content and wrote the paper.